Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy

J Neurooncol. 2003 Jun;63(2):207-11. doi: 10.1023/a:1023912425610.

Abstract

Approximately 20% of patients with Waldenström's macroglobulinemia (WM) have neurological complications; primarily peripheral neuropathies and symptoms related to a hyperviscosity syndrome. We report a rare case of a patient presenting with a slowly progressive myelopathy due to WM who had a marked response to Rituximab therapy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Immunoglobulin M / blood
  • Magnetic Resonance Imaging
  • Male
  • Radiography
  • Rituximab
  • Spinal Cord / diagnostic imaging
  • Spinal Cord / pathology
  • Spinal Cord Diseases / diagnosis
  • Spinal Cord Diseases / drug therapy*
  • Spinal Cord Diseases / etiology*
  • Treatment Outcome
  • Waldenstrom Macroglobulinemia / complications*
  • Waldenstrom Macroglobulinemia / diagnosis
  • Waldenstrom Macroglobulinemia / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Immunoglobulin M
  • Rituximab